Perinatal analyses of Zika- and dengue virus-specific neutralizing antibodies: A microcephaly case-control study in an area of high dengue endemicity in Brazil
Perinatal analyses of Zika- and dengue virus-specific neutralizing antibodies: A microcephaly case-control study in an area of high dengue endemicity in Brazil
复制标题
DOI：
10.1371/journal.pntd.0007246
复制
发表时间：
2019-03-01
影响因子：
3.8
通讯作者：
Brandao Filho, Sinval Pinto
中科院分区：
文献类型：
--
作者：
Castanha, Priscila M. S.;Souza, Wayner V.;Brandao Filho, Sinval Pinto
由于与登革热病毒（DENV）的交叉反应以及对妊娠期抗寨卡抗体反应动力学的了解有限，妊娠期寨卡病毒（ZIKV）感染的实验室确认具有挑战性。我们描述了巴西东北部（2016年）寨卡病毒小头症暴发后，寨卡病毒和DENV血清学标记物以及母亲和新生儿之间抗体的母胎转移。我们纳入了89例小头畸形病例和173例出生时的新生儿对照及其母亲。小头畸形病例被定义为具有特定头围的新生儿（低于平均值2个标准差）。两名没有小头畸形的对照组按预产期和居住地进行匹配。我们检测了母体血清中近期（寨卡病毒基因组、IgM和IgG3抗ns1）和既往（寨卡病毒和DENV中和抗体[nab]）感染标志物。应用主成分分析（PCA）分析了母亲最近或以前感染ZIKV和DENV的多个标记物。分娩时，5.6%的小头畸形病例母亲和1.7%的对照母亲寨卡病毒IgM阳性。寨卡病毒IgG3抗ns1阳性，病例母亲为8.0%，对照组为3.5%。病例母亲寨卡病毒抗体阳性率（69.6%）略高于对照组（57.2%,p = 0.054）。85.8%的母亲暴露于DENV。PCA区分了最近或以前的ZIKV感染和DENV暴露相关的两种不同成分。新生儿的ZIKV抗体高于相应的母亲(p
Laboratory confirmation of Zika virus (ZIKV) infection during pregnancy is challenging due to cross-reactivity with dengue virus (DENV) and limited knowledge about the kinetics of anti-Zika antibody responses during pregnancy. We described ZIKV and DENV serological markers and the maternal-fetal transfer of antibodies among mothers and neonates after the ZIKV microcephaly outbreak in Northeast Brazil (2016). We included 89 microcephaly cases and 173 neonate controls at time of birth and their mothers. Microcephaly cases were defined as newborns with a particular head circumference (2 SD below the mean). Two controls without microcephaly were matched by the expected date of delivery and area of residence. We tested maternal serum for recent (ZIKV genome, IgM and IgG3 anti-NS1) and previous (ZIKV and DENV neutralizing antibodies [NAbs]) markers of infection. Multiple markers of recent or previous ZIKV and DENV infection in mothers were analyzed using principal component analysis (PCA). At delivery, 5.6% of microcephaly case mothers and 1.7% of control mothers were positive for ZIKV IgM. Positivity for ZIKV IgG3 anti-NS1 was 8.0% for case mothers and 3.5% for control mothers. ZIKV NAbs was slightly higher among mothers of cases (69.6%) than that of mothers of controls (57.2%; p = 0.054). DENV exposure was detected in 85.8% of all mothers. PCA discriminated two distinct components related to recent or previous ZIKV infection and DENV exposure. ZIKV NAbs were higher in newborns than in their corresponding mothers (p